MedTrace Logo

CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT02385760 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2016-08-02

No results posted yet for this study

Summary

A multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and safety study of oral CTX-4430 for the treatment of moderate to severe facial acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

CTX-4430

DRUG

Placebo

Sponsors & Collaborators

  • Clinical Network Services (CNS) Pty Ltd

    collaborator INDUSTRY

  • Celtaxsys Aus Pty Limited

    collaborator INDUSTRY

  • Celtaxsys, Inc.

    lead OTHER

Principal Investigators

  • Lynda J Spelman, MB BS, FACD · Veracity Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
44 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-05-31
Completion
2016-08-31

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02385760 on ClinicalTrials.gov